Japanese drugmaker Astellas Pharma sold off its Netherlands manufacturing facility to French CDMO Delpharm Industries for an undisclosed price.
The 46,337-square-meter facility is in Meppel, Netherlands, and employs 332 workers. The plant produces tablets, capsules and granule medicines, the company said in a May 25 press release.
Financial terms of the sale, which is expected to close later this year, were not disclosed. Astellas employees at the site are expected to become part of the Delpharm workforce when the sale is completed.
Delpharm will “continue to manufacture the products that are currently manufactured at the plant in Meppel and will deliver these products to Astellas group to ensure the stable supply of products for patients,” the company said in the release.
In March 2022, Delpharm snapped up its second Canadian manufacturing facility in a deal with Novartis to acquire the drugmaker’s Sandoz manufacturing plant in Quebec. The facility is considered the biggest sterile injectable production facility in the country and supplies drugs to both U.S. and Canadian healthcare systems.